H. Vever

发表

Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients

H. Ditzel, A. Lykkesfeldt, A. Lænkholm, 2015, Breast Cancer Research and Treatment.

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

H. Ditzel, M. Bak, D. Elías, 2022, npj Precision Oncology.

Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy

H. Ditzel, A. Lykkesfeldt, A. Lænkholm, 2014, Oncogene.

Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity

H. Ditzel, P. Parren, A. Labrijn, 2022, Journal for ImmunoTherapy of Cancer.

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

L. Esserman, H. Ditzel, O. Stål, 2021, npj Breast Cancer.

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

L. Esserman, H. Ditzel, J. Andersen, 2021, npj Breast Cancer.

Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy

A. Lykkesfeldt, A. Lænkholm, D. Elías, 2019, Oncogene.

Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes

H. Ditzel, M. Gjerstorff, H. Vever, 2021, Molecular oncology.

Abstract 1887: Global gene expression analysis of tamoxifen-resistant breast cancer cell lines identified a gene signature predictive of clinical outcome of breast cancer patients treated with endocrine therapy

H. Ditzel, A. Lykkesfeldt, H. Vever, 2014 .

Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy

H. Ditzel, A. Lykkesfeldt, A. Lænkholm, 2014, Oncogene.